← 治験一覧に戻る
難治性皮膚潰瘍患者を対象としたPAL-222の臨床試験
基本情報
- NCT ID
- NCT07016438
- ステータス
- 募集中
- 試験のフェーズ
- 該当なし
- 試験タイプ
- 介入
- 目標被験者数
- 6
- 治験依頼者名
- PharmaBio Corporation
概要
The goal of this clinical trial is to assess safety and efficacy in patients with with Refractory skin ulcer no response to existing therapy. The main measures it aims to answer are: * Investigation of adverse events * Changes in clinical testing data * Changes in vital signs Participants will have one PAL-222 transplanted to the ulcer site. Researchers will compare before and after the transplantation to see if any safety issues are recognized.
対象疾患
Refractory Skin Ulcer
介入
Transplant surgery(PROCEDURE)
依頼者（Sponsor）
Pharmabio(INDUSTRY)
実施施設 (1)
京都大学医学部附属病院
Kyoto, Shogoin-kawahara-cho, Sakyo-ku, Kyoto, Japan(RECRUITING)